Seattle Genetics, Genmab sign second ADC deal
This article was originally published in Scrip
Executive Summary
Genmab will pay Seattle Genetics $11m up front with the potential for more than $200m in milestone fees plus royalties on product sales under the Danish company's second antibody-drug conjugate (ADC) agreement with its Bothell, Washington-based partner.